Jennifer A Manuzak1,2, Toni M Gott1,2, Jay S Kirkwood1, Ernesto Coronado1,2, Tiffany Hensley-McBain1,2, Charlene Miller1,2, Ryan K Cheu1,2, Ann C Collier3, Nicholas T Funderburg4, Jeffery N Martin5, Michael C Wu6, Nina Isoherranen1, Peter W Hunt7, Nichole R Klatt1,2. 1. Department of Pharmaceutics, University of Washington. 2. Washington National Primate Research Center. 3. Department of Medicine, Harborview Medical Center, University of Washington, Seattle. 4. School of Health and Rehabilitation Sciences, Division of Medical Laboratory Science, College of Medicine, Ohio State University, Columbus. 5. Department of Epidemiology and Biostatistics, University of California, San Francisco. 6. Public Health Science Division, Fred Hutchinson Cancer Research Center, Seattle, Washington. 7. Department of Medicine, University of California, San Francisco.
Abstract
Background: Cannabis is a widely used drug in the United States, and the frequency of cannabis use in the human immunodeficiency virus (HIV)-infected population is disproportionately high. Previous human and macaque studies suggest that cannabis may have an impact on plasma viral load; however, the relationship between cannabis use and HIV-associated systemic inflammation and immune activation has not been well defined. Methods: The impact of cannabis use on peripheral immune cell frequency, activation, and function was assessed in 198 HIV-infected, antiretroviral-treated individuals by flow cytometry. Individuals were categorized into heavy, medium, or occasional cannabis users or noncannabis users based on the amount of the cannabis metabolite 11-nor-carboxy-tetrahydrocannabinol (THC-COOH) detected in plasma by mass spectrometry. Results: Heavy cannabis users had decreased frequencies of human leukocyte antigen (HLA)-DR+CD38+CD4+ and CD8+ T-cell frequencies, compared to frequencies of these cells in non-cannabis-using individuals. Heavy cannabis users had decreased frequencies of intermediate and nonclassical monocyte subsets, as well as decreased frequencies of interleukin 23- and tumor necrosis factor-α-producing antigen-presenting cells. Conclusions: While the clinical implications are unclear, our findings suggest that cannabis use is associated with a potentially beneficial reduction in systemic inflammation and immune activation in the context of antiretroviral-treated HIV infection.
Background: Cannabis is a widely used drug in the United States, and the frequency of cannabis use in the human immunodeficiency virus (HIV)-infected population is disproportionately high. Previous human and macaque studies suggest that cannabis may have an impact on plasma viral load; however, the relationship between cannabis use and HIV-associated systemic inflammation and immune activation has not been well defined. Methods: The impact of cannabis use on peripheral immune cell frequency, activation, and function was assessed in 198 HIV-infected, antiretroviral-treated individuals by flow cytometry. Individuals were categorized into heavy, medium, or occasional cannabis users or noncannabis users based on the amount of the cannabis metabolite 11-nor-carboxy-tetrahydrocannabinol (THC-COOH) detected in plasma by mass spectrometry. Results: Heavy cannabis users had decreased frequencies of human leukocyte antigen (HLA)-DR+CD38+CD4+ and CD8+ T-cell frequencies, compared to frequencies of these cells in non-cannabis-using individuals. Heavy cannabis users had decreased frequencies of intermediate and nonclassical monocyte subsets, as well as decreased frequencies of interleukin 23- and tumor necrosis factor-α-producing antigen-presenting cells. Conclusions: While the clinical implications are unclear, our findings suggest that cannabis use is associated with a potentially beneficial reduction in systemic inflammation and immune activation in the context of antiretroviral-treated HIV infection.
Authors: Aaron M Kipp; Peter F Rebeiro; Bryan E Shepherd; Lauren Brinkley-Rubinstein; Megan Turner; Sally Bebawy; Timothy R Sterling; Todd Hulgan Journal: AIDS Behav Date: 2017-07
Authors: Angela M Amedee; Whitney A Nichols; Nicole J LeCapitaine; Curtis Vande Stouwe; Leslie L Birke; Nedra Lacour; Peter J Winsauer; Patricia E Molina Journal: AIDS Res Hum Retroviruses Date: 2014-12 Impact factor: 2.205
Authors: Michael M Lederman; Nicholas T Funderburg; Rafick P Sekaly; Nichole R Klatt; Peter W Hunt Journal: Adv Immunol Date: 2013 Impact factor: 3.543
Authors: Patricia E Molina; Angela M Amedee; Peter Winsauer; Steve Nelson; Gregory Bagby; Liz Simon Journal: J Neuroimmune Pharmacol Date: 2015-03-21 Impact factor: 4.147
Authors: David R Lorenz; Anupriya Dutta; Shibani S Mukerji; Alex Holman; Hajime Uno; Dana Gabuzda Journal: Clin Infect Dis Date: 2017-08-15 Impact factor: 9.079
Authors: Thijs Feuth; Joop E Arends; Justin H Fransen; Nening M Nanlohy; Karel J van Erpecum; Peter D Siersema; Andy I M Hoepelman; Debbie van Baarle Journal: PLoS One Date: 2013-03-15 Impact factor: 3.240
Authors: Michael D Rizzo; Joseph E Henriquez; Lance K Blevins; Anthony Bach; Robert B Crawford; Norbert E Kaminski Journal: J Neuroimmune Pharmacol Date: 2020-05-14 Impact factor: 4.147
Authors: Tiffany R Glynn; Maria M Llabre; Jasper S Lee; C Andres Bedoya; Megan M Pinkston; Conall O'Cleirigh; Steven A Safren Journal: Int J Behav Med Date: 2019-06
Authors: Michael D Rizzo; Robert B Crawford; Anthony Bach; Sera Sermet; Andrea Amalfitano; Norbert E Kaminski Journal: J Pharmacol Exp Ther Date: 2019-08-05 Impact factor: 4.030
Authors: Martin Krsak; Nikolas I Wada; Michael W Plankey; Gregory L Kinney; Marta Epeldegui; Chukwuemeka N Okafor; Mackey Reuel Friedman; Frank J Palella; Kristine M Erlandson Journal: Cannabis Cannabinoid Res Date: 2021-04-15
Authors: Jessica S Flannery; Michael C Riedel; Taylor Salo; Ranjita Poudel; Angela R Laird; Raul Gonzalez; Matthew T Sutherland Journal: Prog Neuropsychopharmacol Biol Psychiatry Date: 2021-07-03 Impact factor: 5.067